ACCC COVID-19 Resource Center & Listserv
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Missouri's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 2003
Meetings & Education
Financial Advocacy & Patient Assistance
State & Federal Resources
Off-Label Use Literature
Patient Advocacy Organizations
National Professional Organizations
MOS Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Pembrolizumab for Treatment of Subset of Bladder Cancer Patients
On Jan. 8, 2020, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
Read the FDA announcement
Tweets by OSSatACCC